Platelet inhibitors aggregate

The consensus on Wall Street last week was that Phase III data from Cor Therapeutics Inc.'s PURSUIT trial of its Integrilin GPIIb/IIIa inhibitor in unstable angina give the company an approvable product. The bigger question for CORR is whether it will be able to carve out a piece of the cardiology market from Centocor Inc.'s ReoPro, an antibody that inhibits the same receptor on platelets, as well as other GPIIb/IIIa inhibitors in development.

The additional competition includes Aggrastat tirofiban MK-383 from Merck & Co. (Whitehouse Station, N.J.).

As presented last week, PURSUIT showed a significant reduction in death or heart

Read the full 983 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE